Terns Pharmaceuticals, Inc.

NASDAQ•TERN

CEO: Ms. Amy L. Burroughs M.B.A.

板块: Healthcare

行业: Biotechnology

上市日期: 2021-02-05

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

联系方式

1065 East Hillsdale Boulevard, Suite 100, Foster City, CA, 94404, United States

650-525-5535

www.ternspharma.com

市值

$3.78B

市盈率 (TTM)

-40.8

17.8

股息率

52周最高

$48.26

52周最低

$1.87

52周范围

87%

排名50Top 68.9%

3.1

F-Score

改良版 Piotroski 分析

基于 7 年期基本面

疲弱 • 3.1 / 9 分

评分区间 (0-9)

8-9: 价值优异

6-7: 基本面强劲

4-5: 整体稳健

0-3: 表现疲弱

数据范围: 2019-2025

财务仪表盘

Q3 2025 数据

营业收入

$0.00+0.00%

近4季度走势

每股收益

-$0.27-3.57%

近4季度走势

自由现金流

-$19.77M+20.16%

近4季度走势

2025 Q3 财报亮点

核心亮点

TERN-701 Clinical Data Update Nine-month data shows 75% cumulative MMR rate by 24 weeks in CARDINAL trial efficacy-evaluable patients.

Cash Runway Secured Cash reserves of $150.7M are sufficient to fund planned operating expenses and capital requirements into 2028.

R&D Investment Rises Nine-month R&D expenses increased $6.9M to $59.0M, driven by clinical and preclinical program advancement.

Stock-Based Costs Decline Total stock-based compensation expense was $10.0M for nine months, decreasing from $12.6M prior period.

关注风险

Regulatory Agency Disruption FDA funding cuts and potential government shutdowns could hinder timely guidance and product approval timelines.

Metabolic Asset Pivot Company decided not to advance TERN-601 or invest further in TERN-501 or the TERN-800 series assets.

Substantial Future Funding Expect continued net operating losses requiring substantial additional funding to support ongoing research and development activities.

Trade Policy Uncertainty Evolving global trade policies and tariffs, especially concerning China operations, pose risks to supply chain costs.

前瞻展望

Focus on TERN-701 Advancement Strategy reiterates rapid advancement of TERN-701 program across all Chronic Myeloid Leukemia treatment lines.

Seeking TERN-501 Partner Actively seeking strategic partner to advance TERN-501 program for obesity and other metabolic disorders.

Increased Operating Expenses Expect expenses to increase as development continues for ongoing clinical trials and future regulatory submissions.

同行对比

营业收入 (TTM)

ARVN

$262.60M

-0.3%

SNDX

$172.35M

+627.8%

DAWN

$158.18M

+20.6%

毛利率 (最新季度)

SNDX

102.3%

-13.9pp

IMTX

100.0%

+0.0pp

NKTR

98.3%

+18.4pp

关键指标

股票代码	市值	市盈率 (TTM)	净资产收益率 (TTM)	负债率
ERAS	$4.81B	-34.5	-33.1%	11.5%
TERN	$3.78B	-40.8	-30.0%	0.3%
SNDX	$1.88B	-6.5	-206.6%	65.4%

长期趋势

近4季度

营业收入

净利润

经营现金流

4季度营收复合增长率

N/M

营收波动较大

4季度净利润复合增长率

N/M

盈利状态转变

现金流稳定性

现金流需要关注

深度研究

下次财报:2026年3月19日

每股收益:-$0.30

营业收入:-

财务数据

电话会议

财务报告

新闻

利润表

资产负债表

现金流量表

财务比率

变化率

利润表	过去12个月

无数据